Senator Raffy Tulfo has voiced strong concerns regarding the Food and Drug Administration’s (FDA) inadequate response to the rampant sale of illegal, counterfeit, and unregistered health products both online and in retail locations. During a recent Senate health and demography committee hearing, Tulfo challenged FDA director general Paolo Teston to take more definitive action beyond merely issuing health advisories.
The Danger of Online Sales
Tulfo emphasized the significant risks associated with the convenience of e-commerce platforms, where consumers can easily access a wide range of products. He highlighted how his Senate team successfully purchased prescription-only medications, such as Clobetasol propionate and Co-amoxiclav, on platforms like Shopee without any requirement for a prescription. This alarming ease of access raises serious concerns about public safety.
The Rise of Unregulated Products
The senator also pointed out the increasing popularity of Tirzepatide, particularly through social media channels like TikTok, where unregistered versions are readily available. In the Philippines, only the brand Mounjaro holds FDA registration, yet numerous unregulated alternatives proliferate online, escaping the FDA’s oversight. This situation exemplifies a significant gap in regulatory enforcement, allowing potentially harmful products to saturate the market.
Counterfeit Medicines Persist
Tulfo’s scrutiny extended beyond online sales to physical retail stores. His team conducted test purchases and found that counterfeit medicines, including fake versions of Biogesic, Decolgen Forte, and Neozep, were readily available. Shockingly, these counterfeit products were sometimes priced higher than legitimate medicines, despite being ineffective and posing health risks.
Allegations of Favoritism and Delayed Approvals
Accusations against the FDA have surfaced, suggesting that the agency prioritizes multinational pharmaceutical companies over smaller, local enterprises in the product renewal process. Tulfo claimed that while applications from smaller businesses languish for years, multinational companies receive swift approvals due to alleged corruption. Teston refuted these claims, asserting that FDA personnel act professionally and without bias.
Investigating Complaints and Concerns
Senator Risa Hontiveros, chair of the committee, announced plans to collect complaints regarding delayed applications and allegations of favoritism within the FDA. This investigation aims to ensure that the regulatory landscape is fair and transparent, particularly for small and medium enterprises that are crucial to the local economy.
Insufficient Penalties for Unauthorized Sellers
The penalties for unauthorized sellers of medicines remain minimal, with fines capped at P50,000 and no provision for imprisonment. Franklin Tabaquin IV, acting officer-in-charge of the FDA’s Field Regulatory Operations Office, noted that only a handful of convictions have occurred under relevant laws. This lack of stringent enforcement allows the illicit trade of counterfeit and unregistered products to persist unabated.
The Need for Stricter Regulations
Hontiveros has urged the FDA and major online platforms like Facebook, TikTok, Shopee, and Lazada to take more aggressive action against fake health and beauty products. To address these ongoing issues, she has introduced a Counterfeit Pharmaceutical Products Prevention bill aimed at protecting consumers and enhancing the regulatory framework.
Collaboration with Online Platforms
Representatives from major online platforms acknowledged the existence of “take-down” policies but indicated that these policies primarily rely on consumer complaints for enforcement. This reactive approach raises concerns about the efficacy of current measures, as it allows counterfeit products to remain accessible until flagged by consumers.
Tensions Emerge in Senate Hearing
Tensions escalated during the hearing as Tulfo expressed dissatisfaction with the FDA’s handling of counterfeit medicines sold in local stores. He even questioned Teston about his intent to resign, to which Teston responded that resignation is a voluntary act, emphasizing his commitment to serve under the President’s direction.
Moving Forward
The discussions surrounding the FDA’s regulatory practices underscore the urgent need for reform in the oversight of health products in the Philippines. Strengthening regulations, enhancing penalties for violators, and ensuring timely approvals for all companies will be essential steps in safeguarding public health.
In conclusion, the ongoing dialogue between government officials and regulatory agencies highlights the critical role of effective oversight in protecting consumers from dangerous products. As these discussions progress, it is imperative that the FDA enhances its regulatory framework to address the pressing issues of counterfeit and unregistered health products.
- Key Takeaways:
- Senator Tulfo criticized the FDA for inadequate actions against illegal health products.
- Illicit sales of counterfeit medicines continue to pose serious health risks.
- Allegations of favoritism towards multinational companies raise concerns about fairness in regulatory practices.
- Minimal penalties for unauthorized sellers hinder effective enforcement.
- Legislative efforts are underway to strengthen protections against counterfeit products online.
Read more → www.philstar.com